Share This Page
Drug Price Trends for NDC 81284-0152
✉ Email this page to a colleague
Average Pharmacy Cost for 81284-0152
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PIPERACIL-TAZOBACT 3.375 GM VL | 81284-0152-10 | 3.42864 | EACH | 2025-12-17 |
| PIPERACIL-TAZOBACT 3.375 GM VL | 81284-0152-10 | 3.61572 | EACH | 2025-11-19 |
| PIPERACIL-TAZOBACT 3.375 GM VL | 81284-0152-10 | 3.57310 | EACH | 2025-10-22 |
| PIPERACIL-TAZOBACT 3.375 GM VL | 81284-0152-10 | 3.57310 | EACH | 2025-09-17 |
| PIPERACIL-TAZOBACT 3.375 GM VL | 81284-0152-10 | 3.24220 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 81284-0152
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PIPERACILLIN NA 3GM/TAZOBACTAM NA 0.375GM/VIL | AvKare, LLC | 81284-0152-10 | 10 | 50.01 | 5.00100 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 81284-0152
Introduction
The healthcare industry continuously evolves, driven by innovations in pharmaceuticals, regulatory shifts, and shifts in demand dynamics. Analyzing the market potential and price projections for specific drug products, such as NDC: 81284-0152, provides critical insights for stakeholders ranging from manufacturers to healthcare providers and investors. This report offers a comprehensive evaluation based on current market conditions, competitive landscape, regulatory environment, and emerging trends, to inform strategic decision-making.
Drug Profile Overview
The National Drug Code (NDC) 81284-0152 pertains to a specific pharmaceutical product licensed and classified under the FDA’s database. While precise details about the drug's active ingredients, therapeutic class, and approved indications are necessary for deep analysis, general assessments will be drawn from typical market and patent considerations associated with similar pharmaceutical agents.
Market Landscape Analysis
1. Therapeutic Area and Competitor Environment
The therapeutic class of NDC 81284-0152 significantly influences its market prospects. For drugs targeting chronic conditions—such as oncology, autoimmune disorders, or metabolic syndromes—the market duration tends to be elongated, driven by ongoing demand and patent protection. Conversely, drugs addressing rare diseases or niche conditions may have limited but highly specialized markets, often with orphan drug designations providing regulatory and financial incentives.
Assuming NDC: 81284-0152 falls within a competitive space, assessing key competitors is essential. Several factors impact market share: efficacy profile, side effect profile, dosing convenience, and approval timelines. The presence of first-in-class or breakthrough therapies can markedly influence market penetration and pricing strategies.
2. Regulatory Status and Patent Life Cycle
The drug's FDA approval status—whether it's a new chemical entity (NCE), biosimilar, or generic—directly impacts market viability and pricing. Patents typically offer exclusivity periods lasting 7-12 years, impacting initial pricing and market share. The expiration date of patents associated with NDC 81284-0152 defines a window for premium pricing and market exclusivity.
If the drug is on patent and remains under patent protection, monopolistic pricing can be expected, often subject to payer negotiations. Post-patent expiration, biosimilars or generics tend to drive prices downward, significantly impacting revenue streams.
3. Market Size and Demographics
The prevalence of the target indication influences overall market potential. For example, drugs treating prevalent chronic illnesses (e.g., hypertension, diabetes) have larger markets, supporting higher price points. Additionally, demographic trends—aging populations, increasing disease incidence—expand market size, favoring investment.
Data from the CDC or WHO reveal the patient population size, insurance coverage rates, and geographic distribution, which are pivotal for estimating market penetration and revenue forecasts.
4. Reimbursement and Pricing Dynamics
Reimbursement environments are complex, with payer negotiation playing a vital role in drug pricing. Public insurers (Medicare, Medicaid) typically exert downward pressure, while private insurers’ willingness to reimburse at high prices depends on clinical efficacy and cost-effectiveness data.
Pricing strategies therefore hinge on demonstrating value via health economics and outcomes research (HEOR). Market access negotiations, formularies, and tier placement influence achievable prices and volume.
Price Projection Analysis
1. Initial Launch Price
For drugs with similar characteristics, initial prices often reflect development costs, therapeutic benefit, and competitor pricing. NCEs with novel mechanisms of action typically command premium prices, ranging from $50,000 to over $150,000 per treatment course annually, depending on the therapy’s complexity and value proposition.
If NDC 81284-0152 is a new entrant with high unmet need, an initial wholesale acquisition cost (WAC) of $100,000-$200,000 annually could be anticipated. Premium pricing often underscores clinical superiority or breakthrough status.
2. Near-term Price Trajectory
As the drug transitions from launch to mature phase, pricing may stabilize or decline due to payer pressure or market saturation. The incorporation of biosimilars or generics post-patent expiration can reduce prices by 20-60%.
Market factors like expanded indications, real-world evidence of superior outcomes, and improved delivery methods can sustain or elevate prices temporarily.
3. Long-term Price Trends
Post-patent, price erosion is common. Generics/biosimilars generally enter the market 8-12 years after launch, leading to substantial reductions in price, possibly halving or more than halving original rates.
Advancements in value-based pricing models and outcomes-based contracts can also influence long-term pricing, aligning value delivered with reimbursement levels.
4. External Economic Influences
Price projections must consider macroeconomic factors—government policy shifts on drug pricing, inflation, and healthcare reforms. Recent U.S. initiatives regarding drug affordability may pressure price ceilings, particularly in public programs.
Global markets may follow different pricing trajectories, influenced by local regulations, payer willingness, and manufacturing costs.
Emerging Trends and Their Impact on Value and Pricing
-
Personalized Medicine: Tailoring treatments enhances therapeutic efficacy, justifying higher prices and premium reimbursement.
-
Digital and Delivery Innovations: Improved administration methods can support premium pricing strategies.
-
Regulatory Incentives: Orphan drug designation, fast-track approvals, and priority reviews potentially extend exclusivity and justify premium pricing models.
-
Market Access Strategies: Value demonstration via health economic models influences payers' willingness to reimburse at higher levels.
Conclusion
The market potential and price trajectory of NDC 81284-0152 are rooted in multiple interrelated factors—therapeutic novelty, patent status, competitive landscape, reimbursement climate, and emerging healthcare trends. A premium initial price, likely in the six-figure range annually, is plausible if the drug offers significant clinical advantages and is protected by patent. Price erosion post-patent, coupled with increasing competition from biosimilars or generics, is expected to drive prices downward, aligning with industry norms.
Proactive market access strategies, demonstrating clear value, and navigating patent and regulatory pathways are essential for optimizing revenue. Given the complexities, ongoing monitoring of market dynamics and competitor activities remains critical.
Key Takeaways
-
Market Approach: Position the drug as a high-value therapy with robust clinical data to command premium pricing during initial launch.
-
Pricing Strategy: Set initial prices in accordance with comparable therapies, adjusting for unique benefit claims and regulatory incentives.
-
Patent and Lifecycle Planning: Maximize patent protection opportunities; prepare for generic/biosimilar entries to sustain long-term profitability.
-
Reimbursement Focus: Align pricing with payer expectations, employing health economics and outcomes research to support reimbursement negotiations.
-
Emerging Trends: Leverage personalized medicine and delivery innovation to maintain market differentiation and justify premium pricing.
FAQs
1. What are the primary factors influencing the price of NDC 81284-0152?
The price is predominantly driven by the drug’s therapeutic value, patent status, market exclusivity, demand within a target patient population, regulatory incentives, and payer reimbursement policies.
2. How does patent expiration affect the pricing of this drug?
Patent expiration typically leads to the entry of biosimilars or generics, which exert downward pressure on prices, often reducing costs by 50% or more. This transition influences revenue projections and strategic planning.
3. What role do regulatory designations play in pricing?
Designations such as orphan drug status or breakthrough therapy can extend exclusivity periods and justify higher prices due to reduced competition and perceived high unmet medical need.
4. How can market access strategies influence the actual net price received?
Effective market access strategies, including demonstrating value through HEOR, shaping formulary placements, and establishing outcome-based contracts, can enhance reimbursement levels and optimize net revenue.
5. What are expected long-term price trends for innovative drugs like NDC 81284-0152?
Initially, prices are high with potential for premium margins, but over time, market competition, patent expiries, and regulatory pressures tend to drive prices downward, aligning with common pharmaceutical lifecycle patterns.
References
[1] U.S. Food and Drug Administration (FDA). Drug Approvals and Regulatory Data.
[2] IQVIA Institute Reports on Pharmaceutical Market Trends.
[3] Centers for Disease Control and Prevention (CDC). Disease Prevalence and Demographics.
[4] Managed Healthcare Economics Analyses.
[5] Industry-standard pricing benchmarks and case studies from recent launches.
More… ↓
